Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin i
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
(Date:4/1/2015)... Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: ... raw materials used in the manufacture of traditional Chinese medicine ... financial results for the three- and twelve-months ended December 31, ... 31,Twelve Months Ended December 31, 2014 , 2013 ... $686,669 , $998,934 $4,043,290 , ...
(Date:3/31/2015)... March 31, 2015 Neurocrine Biosciences, Inc. (Nasdaq: ... into an exclusive collaboration and licensing agreement for the ... Japan and other select Asian ... Tanabe intends to initially develop NBI-98854 in ... disease and tardive dyskinesia. Neurocrine retains full commercial rights ...
Breaking Medicine Technology:Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 2Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 4Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 5Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 6Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 7Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 8Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 9Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 10Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 11Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:4/1/2015)... 01, 2015 When you’re suffering from back ... finding some relief. Identifying the causes of lingering back or ... cases, the cause of chronic back pain is due to ... diagnosable causes of back pain and offers many possible treatments, ... president of Atlantic Spine Center . , Dr. Liu ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:3/31/2015)... York (PRWEB) April 01, 2015 Bon ... of Charity to the Schervier Nursing Care Center family ... of Mary the Queen in Yonkers which is scheduled ... Jane Iannucelli, SC, president of the Sisters of Charity ... Charity board of directors to place their Sisters at ...
(Date:3/31/2015)... 2015 Cosmetic Town, one of the ... proudly enduring adding news to its site while it ... of plastic surgery and cosmetic medicine better use and ... interconnected sections, the Cosmetic Town community is tingling at ... Cosmetic Town site navigation, News and Blog section, will ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates ... Commencement ceremony on May 9, 2015 and will ... of her eminent career as a nurse, public health ... and senior staff nurse at Brigham and Women’s Hospital ... roles, including President of the American Nurses Association in ...
Breaking Medicine News(10 mins):Health News:Demystifying Facet Joint Syndrome 2Health News:Demystifying Facet Joint Syndrome 3Health News:Demystifying Facet Joint Syndrome 4Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3
... children are to be weighed, measured and interviewed regarding ... //the growing menace of childhood obesity. The Australian Health ... aged between 7 and 15, are either overweight or ... of heart disease and diabetes. Federal Health Minister Tony ...
... surgeon and a researcher at the children hospital of ... dose anti rejection protocol //has appreciably improved the outcomes ... by Rakesh Sindhi, MD, Co-Director of Pediatric Transplantation, and ... new protocol reduces drug doses and eliminates steroids altogether ...
... up with a new preventive strategy to fight childhood obesity.// ... concern for both the parent and the society. In the ... a program in Meade County, Ky to fight childhood obesity. ... researchers are planning to launch the new program among the ...
... According to the scientist from the Victorian Breast Cancer Research ... have undergone some mutation give rise to the most aggressive ... Hall Institute researchers were working on mouse models when they ... for the female hormones oestrogen or progesterone. This characteristic is ...
... revealed that many popular breakfast cereals contain high levels of ... brands of cereals that were checked for sugar, salt and ... than three-quarters had a high level of sugars, while a ... had high level of saturated fat. ...
... recent announcements by Health Minister, Tony Abbott, to tackle ... has failed to impress AMA President Mukesh// Haikerwal. The ... so that problem can be tackled more effectively. ... new ministerial taskforce for an anti-obesity campaign involving industry ...
Cached Medicine News:Health News:Low Dose Anti Rejection Protocol Helps Intestinal Transplant Recipients 2Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
... Penilab IV and the Penilab V have an exceptionally ... 1060 is similar to the Model 1061 shown below, ... be added later. The Penilab V has a ... the accessories you'll need to get started. Latex ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... MRI-Compatible Anesthesia System is perfect for larger surgery ... type of anesthetic agent. , ,The Integra ... its wider stance, has a larger work area. ... is utilized in both the Integra I and ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
Medicine Products: